Isoflavone bioavailability under controlled whole diet conditions
Not Applicable
- Conditions
- healthy volunteersN95.9Menopausal and perimenopausal disorder, unspecified
- Registration Number
- DRKS00003493
- Lead Sponsor
- Max Rubner-Institut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
postmenopausal women under the age of 75 years; mean BMI of 25 kg/m2; non-smoker; study participants who gave written consent
Exclusion Criteria
hormone replacement therapy; history of breast cancer; serious health problems related to nutrient absorption, digestion, metabolism or excretion; women taking nutritional supplements or on medication during the past 3 months, which may interact with study parameters; participants who are supposed to be not complient
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method isoflavone plasma concentrations (LC-MS/MS), before and after isoflavone/placebo supplementation
- Secondary Outcome Measures
Name Time Method isoflavone metabolites in plasma (LC-MS/MS), before and after isoflavone/placebo supplementation
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What metabolic pathways influence isoflavone bioavailability in menopausal symptom management?
How does isoflavone supplementation compare to HRT in managing menopausal symptoms under controlled diets?
What are the primary endpoints of DRKS00003493 on isoflavone bioavailability and menopausal symptom management?
Which gut microbiota biomarkers correlate with isoflavone bioavailability in postmenopausal women?
How do isoflavones interact with other phytoestrogens in enhancing bioavailability for menopausal disorder treatment?